Therefore, the main aim of this study was to investigate the relation between MET gene amplification and PD-L1 expression in patients with advanced NSCLC and no other actionable oncogenic driver (i.e., EGFR, ALK, ROS1). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.